Ten Year Experience of Radioiodine Dosimetry: is it Useful in the Management of Metastatic Differentiated Thyroid Cancer?

The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis

“…For patients with distant metastases, the use of high 131 I therapy doses allowed a more consistent conclusion to be drawn 7,22. Dosimetry that was calculated using images taken 2, 3, and 7 days after radioiodine seems to be more appropriate for patients with thyroid cancer, especially for pediatric patients with distant metastases 23,24. In our study, a high 131 I dose was used for patients with distant metastases immediately following thyroidectomy.…”

Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response

“…There is a distinct advantage in combining systemically delivered targeted radionuclides and synergistic pharmacologic therapies in an adjuvant setting [49]. This was first proven in the treatment of thyroid cancer, where adjuvant radionuclide therapy in combination with hormone therapy has shown the potential to cure micrometastatic disease [50,51]. This same approach was taken to improve the therapeutic ratio of 223 Ra in the treatment of mCRPC.…”

Clinical trials in molecular radiotherapy—Tribulations and Triumphs Report of the NCRI CTRad meeting held at the Lift Islington, 8 June 2018

“…There is a need to identify the threshold absorbed dose for successful treatment or to implement methods to administer as high as safely achievable activities in combination with lesion dosimetry to avoid under treatment of highrisk patients. 10,11 However, dosimetry is challenging in clinical practice due to the need for extra scanning and resources. More trials are required to assess the efficacy of dosimetry in treatment management.…”